A Randomized, Partially Blinded Phase 2 Trial of Antiretroviral Therapy, HIV‐Specific Immunizations, and Interleukin‐2 Cycles to Promote Efficient Control of Viral Replication (ACTG A5024)

Strategies to limit life‐long dependence on antiretroviral therapy (ART) are needed. We randomized 81 human immunodeficiency virus (HIV)–infected subjects to 4 interventional arms involving continued ART plus ALVAC vCP1452 (or placebo) with or without interleukin (IL)–2 infusions. Viral load rebound...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of infectious diseases 2006-12, Vol.194 (12), p.1672-1676
Main Authors: Kilby, J. Michael , Bucy, R. Pat , Mildvan, Donna , Fischl, Margaret , Santana‐Bagur, Jorge , Lennox, Jeff , Pilcher, Chris , Zolopa, Andrew , Lawrence, Jody , Pollard, Richard B. , Habib, Raphaelle El , Sahner, David , Fox, Lawrence , Aga, Evgenia , Bosch, Ronald J. 
Format: Article
Language:English
Subjects:
Adult
AIDS
AIDS Vaccines - administration & dosage
Anti-HIV Agents - administration & dosage
Anti-HIV Agents - therapeutic use
Anti-Retroviral Agents - therapeutic use
Antiretrovirals
Arts
CD4 Lymphocyte Count
Drug Therapy, Combination
Endpoint Determination
HIV
HIV Infections - immunology
HIV Infections - therapy
HIV Infections - virology
HIV-1 - genetics
HIV-1 - immunology
HIV-1 - isolation & purification
HIV/AIDS
Human immunodeficiency virus
Humans
Immunization
Injections, Subcutaneous
Interleukin-2 - administration & dosage
Interleukin-2 - analogs & derivatives
Interleukin-2 - therapeutic use
Medical treatment
Placebos
Recombinant Proteins - administration & dosage
Recombinant Proteins - therapeutic use
RNA, Viral - blood
T lymphocytes
Treatment Refusal
Vaccination
Viral Load
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c394t-58a7344c2ab60940842d052b37fd353f2896c837a7b473953c3c8316a1cf07c33
cites
container_end_page 1676
container_issue 12
container_start_page 1672
container_title The Journal of infectious diseases
container_volume 194
creator Kilby, J. Michael 
Bucy, R. Pat 
Mildvan, Donna 
Fischl, Margaret 
Santana‐Bagur, Jorge 
Lennox, Jeff 
Pilcher, Chris 
Zolopa, Andrew 
Lawrence, Jody 
Pollard, Richard B. 
Habib, Raphaelle El 
Sahner, David 
Fox, Lawrence 
Aga, Evgenia 
Bosch, Ronald J. 
description Strategies to limit life‐long dependence on antiretroviral therapy (ART) are needed. We randomized 81 human immunodeficiency virus (HIV)–infected subjects to 4 interventional arms involving continued ART plus ALVAC vCP1452 (or placebo) with or without interleukin (IL)–2 infusions. Viral load rebound 12 weeks after ART interruption was then analyzed to assess immune control. Fifty‐two subjects reached the study end point. ALVAC recipients had 0.5 log10 lower virologic rebounds (P=.033). IL‐2 plus vaccine boosted CD4+ T cell counts (P
doi_str_mv 10.1086/509508
format article
fullrecord <record><control><sourceid>jstor_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_68157795</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><jstor_id>30085969</jstor_id><oup_id>10.1086/509508</oup_id><sourcerecordid>30085969</sourcerecordid><originalsourceid>FETCH-LOGICAL-c394t-58a7344c2ab60940842d052b37fd353f2896c837a7b473953c3c8316a1cf07c33</originalsourceid><addsrcrecordid>eNqFkcGO0zAURSMEYsoAfwAyGwRSA892HMfLUk2nlYqoShkhNpHrOBrPJHGwHURnxSfwSXwLX4Jpq5kVYvX03j3v3sVNkqcY3mAo8rcMBIPiXjLCjPI0zzG9n4wACElxIcRJ8sj7KwDIaM4fJieYYxCUFqPk1wStZVfZ1tzoaoxW0gUjm2aH3jWmq3SFVpfSa0TQxsU7sjWadME4HZz9Zly8bC61k_1ujOaLi98_fn7stTK1UWjRtkNnbmQwtvNjFDPQogvaNXq4Nl0kCZruVKM9ChatnG1t0Oisjq9GdwFNbRcj9oEX-5y17huj9nbo1WS6OUcTBiR7_Th5UMvG6yfHeZp8mp1tpvN0-eF8MZ0sU0VFFlJWSE6zTBG5zUFkUGSkAka2lNcVZbQmhchVQbnk24xTwaiiccW5xKoGrig9TV4efHtnvw7ah7I1XummkZ22gy_zAjPO4-P_QCwYIRnwO1A5673Tddk700q3KzGUf0stD6VG8PnRcdi2urrDji1G4MUBsEP_b5NnB-bKB-tuKQpQMJGLqKcH3figv9_q0l2XOaeclfPPX0o648vZ-zWUQP8AGD6_Uw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>19522407</pqid></control><display><type>article</type><title>A Randomized, Partially Blinded Phase 2 Trial of Antiretroviral Therapy, HIV‐Specific Immunizations, and Interleukin‐2 Cycles to Promote Efficient Control of Viral Replication (ACTG A5024)</title><source>Oxford Journals Online</source><creator>Kilby, J. Michael  ; Bucy, R. Pat  ; Mildvan, Donna  ; Fischl, Margaret  ; Santana‐Bagur, Jorge  ; Lennox, Jeff  ; Pilcher, Chris  ; Zolopa, Andrew  ; Lawrence, Jody  ; Pollard, Richard B.  ; Habib, Raphaelle El  ; Sahner, David  ; Fox, Lawrence  ; Aga, Evgenia  ; Bosch, Ronald J. </creator><creatorcontrib>Kilby, J. Michael  ; Bucy, R. Pat  ; Mildvan, Donna  ; Fischl, Margaret  ; Santana‐Bagur, Jorge  ; Lennox, Jeff  ; Pilcher, Chris  ; Zolopa, Andrew  ; Lawrence, Jody  ; Pollard, Richard B.  ; Habib, Raphaelle El  ; Sahner, David  ; Fox, Lawrence  ; Aga, Evgenia  ; Bosch, Ronald J.  ; The Adult AIDS Clinical Trials Group A5024 Protocol Team ; Adult AIDS Clinical Trials Group A5024 Protocol Team ; Adult AIDS Clinical Trials Group A5024 Protocol Team</creatorcontrib><description>Strategies to limit life‐long dependence on antiretroviral therapy (ART) are needed. We randomized 81 human immunodeficiency virus (HIV)–infected subjects to 4 interventional arms involving continued ART plus ALVAC vCP1452 (or placebo) with or without interleukin (IL)–2 infusions. Viral load rebound 12 weeks after ART interruption was then analyzed to assess immune control. Fifty‐two subjects reached the study end point. ALVAC recipients had 0.5 log10 lower virologic rebounds (P=.033). IL‐2 plus vaccine boosted CD4+ T cell counts (P&lt;.001) but did not diminish viral rebound. Significant changes were not detected for HIV‐specific lymphoproliferative responses in any arm. This exploratory protocol provides useful clinical data for future therapeutic immunization trial design.</description><identifier>ISSN: 0022-1899</identifier><identifier>EISSN: 1537-6613</identifier><identifier>DOI: 10.1086/509508</identifier><identifier>PMID: 17109338</identifier><language>eng</language><publisher>United States: University of Chicago Press</publisher><subject><![CDATA[Adult ; AIDS ; AIDS Vaccines - administration & dosage ; Anti-HIV Agents - administration & dosage ; Anti-HIV Agents - therapeutic use ; Anti-Retroviral Agents - therapeutic use ; Antiretrovirals ; Arts ; CD4 Lymphocyte Count ; Drug Therapy, Combination ; Endpoint Determination ; HIV ; HIV Infections - immunology ; HIV Infections - therapy ; HIV Infections - virology ; HIV-1 - genetics ; HIV-1 - immunology ; HIV-1 - isolation & purification ; HIV/AIDS ; Human immunodeficiency virus ; Humans ; Immunization ; Injections, Subcutaneous ; Interleukin-2 - administration & dosage ; Interleukin-2 - analogs & derivatives ; Interleukin-2 - therapeutic use ; Medical treatment ; Placebos ; Recombinant Proteins - administration & dosage ; Recombinant Proteins - therapeutic use ; RNA, Viral - blood ; T lymphocytes ; Treatment Refusal ; Vaccination ; Viral Load]]></subject><ispartof>The Journal of infectious diseases, 2006-12, Vol.194 (12), p.1672-1676</ispartof><rights>Copyright 2006 Infectious Diseases Society of America</rights><rights>2006 by the Infectious Diseases Society of America. All rights reserved. 2006</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c394t-58a7344c2ab60940842d052b37fd353f2896c837a7b473953c3c8316a1cf07c33</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17109338$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kilby, J. Michael </creatorcontrib><creatorcontrib>Bucy, R. Pat </creatorcontrib><creatorcontrib>Mildvan, Donna </creatorcontrib><creatorcontrib>Fischl, Margaret </creatorcontrib><creatorcontrib>Santana‐Bagur, Jorge </creatorcontrib><creatorcontrib>Lennox, Jeff </creatorcontrib><creatorcontrib>Pilcher, Chris </creatorcontrib><creatorcontrib>Zolopa, Andrew </creatorcontrib><creatorcontrib>Lawrence, Jody </creatorcontrib><creatorcontrib>Pollard, Richard B. </creatorcontrib><creatorcontrib>Habib, Raphaelle El </creatorcontrib><creatorcontrib>Sahner, David </creatorcontrib><creatorcontrib>Fox, Lawrence </creatorcontrib><creatorcontrib>Aga, Evgenia </creatorcontrib><creatorcontrib>Bosch, Ronald J. </creatorcontrib><creatorcontrib>The Adult AIDS Clinical Trials Group A5024 Protocol Team</creatorcontrib><creatorcontrib>Adult AIDS Clinical Trials Group A5024 Protocol Team</creatorcontrib><creatorcontrib>Adult AIDS Clinical Trials Group A5024 Protocol Team</creatorcontrib><title>A Randomized, Partially Blinded Phase 2 Trial of Antiretroviral Therapy, HIV‐Specific Immunizations, and Interleukin‐2 Cycles to Promote Efficient Control of Viral Replication (ACTG A5024)</title><title>The Journal of infectious diseases</title><addtitle>The Journal of Infectious Diseases</addtitle><addtitle>The Journal of Infectious Diseases</addtitle><description>Strategies to limit life‐long dependence on antiretroviral therapy (ART) are needed. We randomized 81 human immunodeficiency virus (HIV)–infected subjects to 4 interventional arms involving continued ART plus ALVAC vCP1452 (or placebo) with or without interleukin (IL)–2 infusions. Viral load rebound 12 weeks after ART interruption was then analyzed to assess immune control. Fifty‐two subjects reached the study end point. ALVAC recipients had 0.5 log10 lower virologic rebounds (P=.033). IL‐2 plus vaccine boosted CD4+ T cell counts (P&lt;.001) but did not diminish viral rebound. Significant changes were not detected for HIV‐specific lymphoproliferative responses in any arm. This exploratory protocol provides useful clinical data for future therapeutic immunization trial design.</description><subject>Adult</subject><subject>AIDS</subject><subject>AIDS Vaccines - administration &amp; dosage</subject><subject>Anti-HIV Agents - administration &amp; dosage</subject><subject>Anti-HIV Agents - therapeutic use</subject><subject>Anti-Retroviral Agents - therapeutic use</subject><subject>Antiretrovirals</subject><subject>Arts</subject><subject>CD4 Lymphocyte Count</subject><subject>Drug Therapy, Combination</subject><subject>Endpoint Determination</subject><subject>HIV</subject><subject>HIV Infections - immunology</subject><subject>HIV Infections - therapy</subject><subject>HIV Infections - virology</subject><subject>HIV-1 - genetics</subject><subject>HIV-1 - immunology</subject><subject>HIV-1 - isolation &amp; purification</subject><subject>HIV/AIDS</subject><subject>Human immunodeficiency virus</subject><subject>Humans</subject><subject>Immunization</subject><subject>Injections, Subcutaneous</subject><subject>Interleukin-2 - administration &amp; dosage</subject><subject>Interleukin-2 - analogs &amp; derivatives</subject><subject>Interleukin-2 - therapeutic use</subject><subject>Medical treatment</subject><subject>Placebos</subject><subject>Recombinant Proteins - administration &amp; dosage</subject><subject>Recombinant Proteins - therapeutic use</subject><subject>RNA, Viral - blood</subject><subject>T lymphocytes</subject><subject>Treatment Refusal</subject><subject>Vaccination</subject><subject>Viral Load</subject><issn>0022-1899</issn><issn>1537-6613</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><recordid>eNqFkcGO0zAURSMEYsoAfwAyGwRSA892HMfLUk2nlYqoShkhNpHrOBrPJHGwHURnxSfwSXwLX4Jpq5kVYvX03j3v3sVNkqcY3mAo8rcMBIPiXjLCjPI0zzG9n4wACElxIcRJ8sj7KwDIaM4fJieYYxCUFqPk1wStZVfZ1tzoaoxW0gUjm2aH3jWmq3SFVpfSa0TQxsU7sjWadME4HZz9Zly8bC61k_1ujOaLi98_fn7stTK1UWjRtkNnbmQwtvNjFDPQogvaNXq4Nl0kCZruVKM9ChatnG1t0Oisjq9GdwFNbRcj9oEX-5y17huj9nbo1WS6OUcTBiR7_Th5UMvG6yfHeZp8mp1tpvN0-eF8MZ0sU0VFFlJWSE6zTBG5zUFkUGSkAka2lNcVZbQmhchVQbnk24xTwaiiccW5xKoGrig9TV4efHtnvw7ah7I1XummkZ22gy_zAjPO4-P_QCwYIRnwO1A5673Tddk700q3KzGUf0stD6VG8PnRcdi2urrDji1G4MUBsEP_b5NnB-bKB-tuKQpQMJGLqKcH3figv9_q0l2XOaeclfPPX0o648vZ-zWUQP8AGD6_Uw</recordid><startdate>20061215</startdate><enddate>20061215</enddate><creator>Kilby, J. Michael </creator><creator>Bucy, R. Pat </creator><creator>Mildvan, Donna </creator><creator>Fischl, Margaret </creator><creator>Santana‐Bagur, Jorge </creator><creator>Lennox, Jeff </creator><creator>Pilcher, Chris </creator><creator>Zolopa, Andrew </creator><creator>Lawrence, Jody </creator><creator>Pollard, Richard B. </creator><creator>Habib, Raphaelle El </creator><creator>Sahner, David </creator><creator>Fox, Lawrence </creator><creator>Aga, Evgenia </creator><creator>Bosch, Ronald J. </creator><general>University of Chicago Press</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7U9</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>20061215</creationdate><title>A Randomized, Partially Blinded Phase 2 Trial of Antiretroviral Therapy, HIV‐Specific Immunizations, and Interleukin‐2 Cycles to Promote Efficient Control of Viral Replication (ACTG A5024)</title><author>Kilby, J. Michael  ; Bucy, R. Pat  ; Mildvan, Donna  ; Fischl, Margaret  ; Santana‐Bagur, Jorge  ; Lennox, Jeff  ; Pilcher, Chris  ; Zolopa, Andrew  ; Lawrence, Jody  ; Pollard, Richard B.  ; Habib, Raphaelle El  ; Sahner, David  ; Fox, Lawrence  ; Aga, Evgenia  ; Bosch, Ronald J. </author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c394t-58a7344c2ab60940842d052b37fd353f2896c837a7b473953c3c8316a1cf07c33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Adult</topic><topic>AIDS</topic><topic>AIDS Vaccines - administration &amp; dosage</topic><topic>Anti-HIV Agents - administration &amp; dosage</topic><topic>Anti-HIV Agents - therapeutic use</topic><topic>Anti-Retroviral Agents - therapeutic use</topic><topic>Antiretrovirals</topic><topic>Arts</topic><topic>CD4 Lymphocyte Count</topic><topic>Drug Therapy, Combination</topic><topic>Endpoint Determination</topic><topic>HIV</topic><topic>HIV Infections - immunology</topic><topic>HIV Infections - therapy</topic><topic>HIV Infections - virology</topic><topic>HIV-1 - genetics</topic><topic>HIV-1 - immunology</topic><topic>HIV-1 - isolation &amp; purification</topic><topic>HIV/AIDS</topic><topic>Human immunodeficiency virus</topic><topic>Humans</topic><topic>Immunization</topic><topic>Injections, Subcutaneous</topic><topic>Interleukin-2 - administration &amp; dosage</topic><topic>Interleukin-2 - analogs &amp; derivatives</topic><topic>Interleukin-2 - therapeutic use</topic><topic>Medical treatment</topic><topic>Placebos</topic><topic>Recombinant Proteins - administration &amp; dosage</topic><topic>Recombinant Proteins - therapeutic use</topic><topic>RNA, Viral - blood</topic><topic>T lymphocytes</topic><topic>Treatment Refusal</topic><topic>Vaccination</topic><topic>Viral Load</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kilby, J. Michael </creatorcontrib><creatorcontrib>Bucy, R. Pat </creatorcontrib><creatorcontrib>Mildvan, Donna </creatorcontrib><creatorcontrib>Fischl, Margaret </creatorcontrib><creatorcontrib>Santana‐Bagur, Jorge </creatorcontrib><creatorcontrib>Lennox, Jeff </creatorcontrib><creatorcontrib>Pilcher, Chris </creatorcontrib><creatorcontrib>Zolopa, Andrew </creatorcontrib><creatorcontrib>Lawrence, Jody </creatorcontrib><creatorcontrib>Pollard, Richard B. </creatorcontrib><creatorcontrib>Habib, Raphaelle El </creatorcontrib><creatorcontrib>Sahner, David </creatorcontrib><creatorcontrib>Fox, Lawrence </creatorcontrib><creatorcontrib>Aga, Evgenia </creatorcontrib><creatorcontrib>Bosch, Ronald J. </creatorcontrib><creatorcontrib>The Adult AIDS Clinical Trials Group A5024 Protocol Team</creatorcontrib><creatorcontrib>Adult AIDS Clinical Trials Group A5024 Protocol Team</creatorcontrib><creatorcontrib>Adult AIDS Clinical Trials Group A5024 Protocol Team</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>The Journal of infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kilby, J. Michael </au><au>Bucy, R. Pat </au><au>Mildvan, Donna </au><au>Fischl, Margaret </au><au>Santana‐Bagur, Jorge </au><au>Lennox, Jeff </au><au>Pilcher, Chris </au><au>Zolopa, Andrew </au><au>Lawrence, Jody </au><au>Pollard, Richard B. </au><au>Habib, Raphaelle El </au><au>Sahner, David </au><au>Fox, Lawrence </au><au>Aga, Evgenia </au><au>Bosch, Ronald J. </au><aucorp>The Adult AIDS Clinical Trials Group A5024 Protocol Team</aucorp><aucorp>Adult AIDS Clinical Trials Group A5024 Protocol Team</aucorp><aucorp>Adult AIDS Clinical Trials Group A5024 Protocol Team</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A Randomized, Partially Blinded Phase 2 Trial of Antiretroviral Therapy, HIV‐Specific Immunizations, and Interleukin‐2 Cycles to Promote Efficient Control of Viral Replication (ACTG A5024)</atitle><jtitle>The Journal of infectious diseases</jtitle><stitle>The Journal of Infectious Diseases</stitle><addtitle>The Journal of Infectious Diseases</addtitle><date>2006-12-15</date><risdate>2006</risdate><volume>194</volume><issue>12</issue><spage>1672</spage><epage>1676</epage><pages>1672-1676</pages><issn>0022-1899</issn><eissn>1537-6613</eissn><abstract>Strategies to limit life‐long dependence on antiretroviral therapy (ART) are needed. We randomized 81 human immunodeficiency virus (HIV)–infected subjects to 4 interventional arms involving continued ART plus ALVAC vCP1452 (or placebo) with or without interleukin (IL)–2 infusions. Viral load rebound 12 weeks after ART interruption was then analyzed to assess immune control. Fifty‐two subjects reached the study end point. ALVAC recipients had 0.5 log10 lower virologic rebounds (P=.033). IL‐2 plus vaccine boosted CD4+ T cell counts (P&lt;.001) but did not diminish viral rebound. Significant changes were not detected for HIV‐specific lymphoproliferative responses in any arm. This exploratory protocol provides useful clinical data for future therapeutic immunization trial design.</abstract><cop>United States</cop><pub>University of Chicago Press</pub><pmid>17109338</pmid><doi>10.1086/509508</doi><tpages>5</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0022-1899
ispartof The Journal of infectious diseases, 2006-12, Vol.194 (12), p.1672-1676
issn 0022-1899
1537-6613
language eng
recordid cdi_proquest_miscellaneous_68157795
source Oxford Journals Online
subjects Adult
AIDS
AIDS Vaccines - administration & dosage
Anti-HIV Agents - administration & dosage
Anti-HIV Agents - therapeutic use
Anti-Retroviral Agents - therapeutic use
Antiretrovirals
Arts
CD4 Lymphocyte Count
Drug Therapy, Combination
Endpoint Determination
HIV
HIV Infections - immunology
HIV Infections - therapy
HIV Infections - virology
HIV-1 - genetics
HIV-1 - immunology
HIV-1 - isolation & purification
HIV/AIDS
Human immunodeficiency virus
Humans
Immunization
Injections, Subcutaneous
Interleukin-2 - administration & dosage
Interleukin-2 - analogs & derivatives
Interleukin-2 - therapeutic use
Medical treatment
Placebos
Recombinant Proteins - administration & dosage
Recombinant Proteins - therapeutic use
RNA, Viral - blood
T lymphocytes
Treatment Refusal
Vaccination
Viral Load
title A Randomized, Partially Blinded Phase 2 Trial of Antiretroviral Therapy, HIV‐Specific Immunizations, and Interleukin‐2 Cycles to Promote Efficient Control of Viral Replication (ACTG A5024)
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-30T04%3A45%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-jstor_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20Randomized,%20Partially%20Blinded%20Phase%202%20Trial%20of%20Antiretroviral%20Therapy,%20HIV%E2%80%90Specific%20Immunizations,%20and%20Interleukin%E2%80%902%20Cycles%20to%20Promote%20Efficient%20Control%20of%20Viral%20Replication%20(ACTG%20A5024)&rft.jtitle=The%20Journal%20of%20infectious%20diseases&rft.au=Kilby,%20J.%C2%A0Michael%C2%A0&rft.aucorp=The%20Adult%20AIDS%20Clinical%20Trials%20Group%20A5024%20Protocol%20Team&rft.date=2006-12-15&rft.volume=194&rft.issue=12&rft.spage=1672&rft.epage=1676&rft.pages=1672-1676&rft.issn=0022-1899&rft.eissn=1537-6613&rft_id=info:doi/10.1086/509508&rft_dat=%3Cjstor_proqu%3E30085969%3C/jstor_proqu%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c394t-58a7344c2ab60940842d052b37fd353f2896c837a7b473953c3c8316a1cf07c33%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=19522407&rft_id=info:pmid/17109338&rft_jstor_id=30085969&rft_oup_id=10.1086/509508&rfr_iscdi=true